Kymera Therapeutics (KYMR) EBIAT (2019 - 2025)
Kymera Therapeutics (KYMR) has disclosed EBIAT for 7 consecutive years, with -$87.0 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 22.94% to -$87.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$311.4 million through Dec 2025, down 39.08% year-over-year, with the annual reading at -$311.4 million for FY2025, 39.08% down from the prior year.
- EBIAT for Q4 2025 was -$87.0 million at Kymera Therapeutics, down from -$82.2 million in the prior quarter.
- The five-year high for EBIAT was -$13.1 million in Q1 2021, with the low at -$87.0 million in Q4 2025.
- Average EBIAT over 5 years is -$46.9 million, with a median of -$41.5 million recorded in 2023.
- The sharpest move saw EBIAT soared 58.79% in 2023, then plummeted 392.43% in 2024.
- Over 5 years, EBIAT stood at -$33.9 million in 2021, then decreased by 2.85% to -$34.9 million in 2022, then skyrocketed by 58.79% to -$14.4 million in 2023, then plummeted by 392.43% to -$70.8 million in 2024, then dropped by 22.94% to -$87.0 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$87.0 million, -$82.2 million, and -$76.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.